Back to results
US 2019/0055522 A1Published application
Use of adenovirus and nucleic acids coding therefor
OwnerPer Sonne Holminventor
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or ongogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
Claims15
1-55. (canceled)
A method for the treatment of cancer, the method comprising:
- administering to a subject in need thereof an adenovirus, wherein the adenovirus expresses E1B55kDa and is replication deficient in cells that lack Y box binding protein 1 (YB-1) in the nucleus and replication competent in cells that have YB-1 in the nucleus;
- wherein the virus encodes an oncogene protein that transactivates E1B55kDa, and wherein the adenovirus is dl520 lacking a functional CR3 domain.
Dependencies are inferred from the claim text.